Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes—Interventional Study
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) is associated with the excessive collection of lipids in hepatocytes. Over 75% of diabetes patients typically have MASLD, and, at the same time, the presence of MASLD increases the risk of diabetes by more than two times. Type 2 diabet...
Main Authors: | Marcin Hachuła, Michał Kosowski, Marcin Basiak, Bogusław Okopień |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-08-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/16/9/1190 |
Similar Items
-
Impact of Glucagon-Like Peptide 1 Receptor Agonists on Biochemical Markers of the Initiation of Atherosclerotic Process
by: Marcin Hachuła, et al.
Published: (2024-02-01) -
Glucagon-like Peptide-1 Receptor Agonists—A Potential New Medication for Pediatric Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Erika Choi, et al.
Published: (2024-02-01) -
Lipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD)
by: Majid Mufaqam Syed-Abdul
Published: (2023-12-01) -
Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY<sub>3-36</sub>, and Empagliflozin on Early MASLD in Diet-Induced Obese Rats
by: Simon Kloock, et al.
Published: (2024-03-01) -
The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies
by: Peng Jiang, et al.
Published: (2024-05-01)